Monday, November 6, 2017
- 2:30PM-4:00PM
-
Abstract Number: 1813
Rates of Contraceptive Use and Unintended Pregnancy in Teen Girls Prescribed Teratogenic Medications
Reproductive Issues in Rheumatic Disorders- 2:30PM-4:00PM
-
Abstract Number: 1826
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II- 2:30PM-4:00PM
-
Abstract Number: 1828
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II- 2:30PM-4:00PM
-
Abstract Number: 1834
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Systemic Lupus Erythematosus – Animal Models- 2:30PM-4:00PM
-
Abstract Number: 1843
Serum Albumin at 12 Months Post Biopsy Has Excellent Sensitivity and Specificity for Favorable 4 Year Renal Outcome in Lupus Nephritis (LN)
Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures- 2:30PM-4:00PM
-
Abstract Number: 1816
Sex Differences in Orthopedic Surgery Among Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects II: Treatment Patterns- 2:30PM-4:00PM
-
Abstract Number: 1790
Sphingosine -1 Phosphate Receptor-1-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Unexpected Effects from "Well-Known" Molecules- 2:30PM-4:00PM
-
Abstract Number: 1842
Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity
Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures- 2:30PM-4:00PM
-
Abstract Number: 1820
Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Outcomes Therapy- 2:30PM-4:00PM
-
Abstract Number: 1791
TET1 Is an Important Transcriptional Activator of the Tnfa Locus in Macrophages
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis: Unexpected Effects from "Well-Known" Molecules- 2:30PM-4:00PM
-
Abstract Number: 1822
The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Outcomes Therapy- 2:30PM-4:00PM
-
Abstract Number: 1847
The IgG4:IgG RNA Ratio in Peripheral Blood Perfectly Differentiates Active Disease from Remission in Granulomatosis with Polyangiitis. a New Disease Activity Marker?
Vasculitis II: Biomarkers and Disease Activity- 2:30PM-4:00PM
-
Abstract Number: 1799
Time to First Appointment Among Young Adults Transitioning from Pediatric to Adult Rheumatologic Care in a Safety Net Population
Measures and Measurement of Healthcare Quality- 2:30PM-4:00PM
-
Abstract Number: 1814
Time Trends over a Decade Show Earlier Intensified Medication Strategies and Improved Outcomes in Canadians with Early Inflammatory Arthritis